Study: Popular diabetes treatment is not associated with thyroid cancer

Concerns raised about an association between GLP-1 analogues, used to treat diabetes and obesity, and an increased risk of thyroid cancer are not supported by a...

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

“Research is always a lot of failures and a few successes”

Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

QPS Netherlands B.V

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

EQT säljer Karo Healthcare för 27 miljarder

Riskkapitalbolaget KKR förvärvar det svenska konsumenthälsobolaget Karo Healthcare från EQT.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

We will now publish more news in English – and offer yet another newsletter

Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.

Doge backar om nedläggning av viktigt FDA-labb

Trumpadministrationen drar efter kritik tillbaka beslutet att stänga ett av FDA:s viktigaste laboratorier för läkemedelskontroll.

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

USA upprättar databas över autismpatienter – ska forska kring orsakerna

USA:s hälsomyndigheter ska skapa en databas över autismpatienter för att kunna studera orsakerna till diagnosen. Det meddelade landets hälsominister Robert F. K...

Save the dates: ZEISS Quality Innovation Summit, October 22-24

Embark on a journey to the future of metrology.

BMS planerar investera nära 400 miljarder i USA

Under måndagen meddelade Bristol Myers Squibb att bolaget planerar att investera 40 miljarder dollar, motsvarande 387 miljarder svenska kronor, i USA under de k...

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.